Ocular Therapeutix
OCUL
75 hedge funds and large institutions have $96.4M invested in Ocular Therapeutix in 2016 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 11 reducing their positions, and 7 closing their positions.
209% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 11
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
71% more call options, than puts
Call options by funds: $403K | Put options by funds: $236K
17% more funds holding
Funds holding: 64 → 75 (+11)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
52% less capital invested
Capital invested by funds: $201M → $96.4M (-$104M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$16.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.27M |
| 3 |
PGCM
Prescott Group Capital Management
Tulsa,
Oklahoma
|
+$3.5M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.58M |
| 5 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$2.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$27.7M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$19.6M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.49M |
| 4 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
-$2.29M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$821K |
OCUL Hedge Fund Activity: Q2 2016 in Review
75 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q2 2016, worth a combined $96.4M — down 52% from $201M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new OCUL positions and 7 closed out — a net gain of 11 holders — while 34 added to existing stakes and 11 trimmed.
The largest buyer was Jennison Associates, adding an estimated $16.3M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $27.7M sold.
- 75 institutional investors held Ocular Therapeutix (OCUL) as of Q2 2016, up from 64 in Q1 2016.
- Funds reported $96.4M of Ocular Therapeutix stock for Q2 2016, down 52% quarter-over-quarter.
- 18 funds opened new Ocular Therapeutix positions in Q2 2016 and 7 closed out, a net change of +11 holders.
- The largest Ocular Therapeutix buyer in Q2 2016 was Jennison Associates, an estimated $16.3M added.
- The largest Ocular Therapeutix seller in Q2 2016 was Capital Research Global Investors, an estimated $27.7M sold.
Based on aggregated 13F filings for Q2 2016.